GlobalData has named heart failure as the next disease to feel the sales-boosting power of GLP-1 drugs. The analysts expect ...

It’s not at all clear what a tariff would mean for Novo, which manufactures its medicines in facilities all over the world, ...

New tests may show how much value a particular obese patient will get for a GLP-1 agonist prescription dollar.

Experimental weight-loss drug Retatrutide shows promise, helping obese adults lose up to 22% of their weight in 48 weeks.

The startup, which has already raised more than half a billion dollars, released Phase 2 results that could position its drug ...

How GLP-1 therapies could help build a healthier, more productive workforce—and what that would mean for how we live together ...

A new trend gaining popularity among people trying to lose weight is microdosing the diabetes medication Ozempic. Experts ...

While West Virginia's employee health insurance program covers drugs like Ozempic for people with type 2 diabetes, officials ...